Core Insights - Stryker has announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, expanding its Mako robotics platform into a new segment [1][2] - Mako RPS is compatible with Stryker's Triathlon Total Knee System and aims to provide surgeons with the benefits of robotic technology while maintaining the familiarity of manual power tools [2][3] Company Overview - Stryker is a global leader in medical technologies, impacting over 150 million patients annually through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [5] - The company emphasizes its commitment to advancing orthopaedic patient outcomes through robotics, with nearly 20 years of experience and over 2 million procedures performed globally [3] Product Features - Mako RPS for Total Knee includes intraoperative planning and a robotically enabled saw that utilizes Stryker's patented active adjustment technology, aligning with the surgical plan based on the surgeon's hand movements [3] - The system integrates seamlessly into a surgeon's workflow, providing a familiar cutting experience without the need for cutting blocks, and is designed to work with Stryker's Q Guidance System [3]

Group 1 - Stryker Corporation (NYSE:SYK) is recognized as one of the top 12 Medical Devices stocks to invest in according to Hedge Funds [1] - Matthew O'Brien from Piper Sandler has reiterated an Overweight rating on Stryker with a price target of $420, indicating over 17% upside potential for investors [1][2] - The company is introducing a new handheld orthopedic robot, Mako RPS, which is expected to enhance its market presence in lower-cost segments, including ambulatory surgical centers and select international markets [2] Group 2 - Evercore ISI has maintained an Outperform rating on Stryker while adjusting the target price from $405 to $390, citing recoveries in end markets and anticipated healthy capital expenditures in the medical technology sector for 2026 [3] - Stryker operates in two segments: MedSurg & Neurotechnology and Orthopaedic, focusing on innovative products to improve patient outcomes [4]

Core Insights - Stryker Corporation reported strong fourth-quarter 2025 results with adjusted EPS of $4.47, exceeding estimates and showing an 11.5% year-over-year improvement [1] - The company achieved revenues of $7.17 billion, beating consensus estimates and reflecting an 11.4% year-over-year growth [2] Financial Performance - Adjusted EPS for the full year increased by 11.8% to $13.63, while GAAP EPS rose 8.2% to $8.40 [1] - Revenues for the full year reached $25.1 billion, marking an 11.2% increase year-over-year [2] Revenue Breakdown - U.S. revenues were $5.44 billion, up 11.7% year-over-year, while international sales increased by 10.6% to $1.73 billion [3] - Organic sales growth was driven by a 10.9% increase in unit volume and a 0.1% improvement in prices [2] Segment Analysis - The MedSurg and Neurotechnology segment reported sales of $4.6 billion, up 17.5% year-over-year [5] - Orthopedics segment sales amounted to $2.61 billion, reflecting a 2.2% year-over-year increase [10] Margins and Expenses - Adjusted gross profit was $4.68 billion, up 11.3% year-over-year, with adjusted gross margin at 65.2% [12] - Total operating expenses decreased by 21.4% to $2.82 billion [12] Financial Position - Cash and cash equivalents at the end of the fourth quarter were $4.01 billion, up from $3.26 billion at the end of the previous quarter [14] - Cumulative net cash from operating activities totaled $5.04 billion, compared to $4.24 billion a year ago [14] 2026 Guidance - Stryker expects total revenues to grow between 8-9.5% on an organic basis for 2026, with EPS projected in the range of $14.90 to $15.10 [15] - The Zacks Consensus Estimate for total revenues is $27.23 billion, implying an 8.6% growth [15] Market Position and Growth Drivers - Stryker is positioned for durable growth in global MedTech, driven by robotics adoption and a strong capital cycle [17] - The Mako robotic system's adoption continues to deepen, with over 3,000 systems installed globally [18] - New applications for Mako are set to launch in mid-2026, expanding the addressable market [19] Pricing and Margin Outlook - Management anticipates pricing improvements in 2026 similar to those in 2025, with new product launches potentially at higher price points [20] - Stryker expects to expand margins despite a $400 million tariff headwind in 2026 [21]